NCT03684395

Accessibility to New Drugs Versus SOC in Sweden

Association Between Socioeconomic Factors and Use of Direct Oral Anticoagulants Versus Standard of Care (Warfarin) in Patients With Non-valvular Atrial Fibrillation in Sweden

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 68,056 (actual)
• Sponsor: Bayer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The healthcare system in Sweden is publicly funded and aims to provide equal access to care irrespective of socioeconomic status. This includes ensuring equity in drug treatment. Socioeconomic disparities have been shown to influence patient management and health outcomes in certain Swedish populations. The Swedish Board of Health and Welfare has stated that the prescription of new drugs, which are more expensive than generic standard of care drugs, might be influenced by patients' socioeconomic status. To evaluate the association between socioeconomic factors and use of a DOAC (rivaroxaban, dabigatran, or apixaban) or standard of care (warfarin) in patients with NVAF in Sweden.

Conditions

• Anticoagulation

Interventions

Type	Name	Description
DRUG	DOACs: Rivaroxaban, Dabigatran, Apixaban	Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
DRUG	Standard of care (Warfarin)	Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection

Timeline

• Start date: 2016-06-15
• Primary completion: 2017-06-30
• Completion: 2017-06-30
• First posted: 2018-09-25
• Last updated: 2019-03-29

Locations

1 site across 1 country: Sweden